In univariate analysis, positive factors in patients with good efficacy (DCR) included NSCLC diagnosis (p = 0.012), higher PD-L1 expression level (p = 0.006), and use of anti-PD-L1 inhibitors (p = 0.001) as first-line treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.